GlaxoSmithKline picks up NICE recommendation for Strimvelis, a €594,000 gene therapy

23rd October 2017 Uncategorised 0

Despite being one of the most expensive drugs in the world, GlaxoSmithKline’s gene therapy Strimvelis won the backing of the often stingy U.K. cost watchdogs to treat a rare disease called ADA-SCID, or “bubble boy” syndrome. The drug, which costs €594,000 (about $700,000), is a one-time treatment that the overseers said is worth the money because of survival rates and other benefits.

More: GlaxoSmithKline picks up NICE recommendation for Strimvelis, a €594,000 gene therapy
Source: fierce